Company intelligence / Profile preview

Predica Diagnostics

Nijmegen, Netherlandspredica-diagnostics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Proof-of-principle studies show that the CervicaDx test can differentiate between hrHPV-positive women with no viral activity/aberrations and those at risk due to active virus/integration. The test also measures activity of ~250 cancer-related genes to improve specificity over current screening methods. Validation and regulatory approval are ongoing.

Therapeutic areas: Oncology
Modalities: Diagnostic assay (ciRNAseq technology)mRNA-based diagnostic testSoftware algorithm (for risk prediction and treatment guidance)
Industry: Molecular Diagnostics

Drug pipeline

3 assets

HPV Profiler

Pre-clinical

Indications: HPV detection

2 more assets in the full pipeline.

Request access →

Partnerships

Radboudumc (spin-off origin/academic partnership)

Beyond the preview

Go deeper on Predica Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Predica Diagnostics.

Explore the full profile